Comparative Pharmacology
Head-to-head clinical analysis: KENALOG versus LIQUID PRED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KENALOG versus LIQUID PRED.
KENALOG vs LIQUID PRED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Triamcinolone acetonide is a synthetic corticosteroid with potent glucocorticoid and weak mineralocorticoid activity. It binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2, decreased release of arachidonic acid, and reduced synthesis of prostaglandins and leukotrienes. It also suppresses cytokine production and immune cell migration.
Prednisolone is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators (cytokines, prostaglandins, leukotrienes).
Kenalog (triamcinolone acetonide) 40-80 mg intramuscularly (deep gluteal) every 4 weeks; or 0.5-1 mg/kg intravenously every 24 hours (for acute conditions).
5-60 mg/day orally in divided doses; typical starting dose 5-10 mg every 6-12 hours.
None Documented
None Documented
Terminal half-life ~2-5 hours (triamcinolone acetonide); clinical duration prolonged due to crystalline depot formulation
2.1–3.5 hours (terminal elimination half-life; shorter half-life in children; prolonged in hepatic impairment).
Renal (primarily as metabolites), ~30% unchanged; biliary/fecal minor (≤10%)
Primarily renal: prednisolone is excreted as glucuronide and sulfate conjugates; less than 1% unchanged. Biliary/fecal excretion accounts for <5%.
Category C
Category C
Corticosteroid
Corticosteroid